Description of the medicine: Medroxyprogesterone acetate (Medroxyprogesterone acetate)
MEDROXIPROGESTERONE ACETATE (Medroxyprogesterone acetate). 17-Hydroxy-6 a-methylpregn-4-en-3, 20-dione acetate.
Synonyms: Depo-Provera, Provera, Farlutal, Clinovir, Depcorlutin, Depo-Alphacort, Depo-Clinovie, Depo-Promone, Depo-Provera, Farlutal, Farmolut, Gestopuran, Luteodione, Metilgestene, Neolut, Nidaxin, Normobra, Onco, Prodafem, Promone-E, Provera, Proverone, Sedometril, Vadecin, etc.
In chemical structure it is close to progesterone derivatives (see). In its main form of action, it is progestin (progestogen). As a gestagenic agent, it is used for menstrual irregularities, dysfunctional uterine bleeding. However, the drug found its main use as an antitumor agent for hormone-sensitive malignant tumors (see Progesterone capronate), especially for breast and uterine cancer (endometrium). The effect is associated not only with gestagen, but also with anti-estrogenic, antiandrogenic and anti-agonadotropic activity.
In breast cancer, there is a correlation between the effectiveness of medroxyprogesterone and the concentration of estrogen and progesterone receptors in the tumor tissue.
The drug can be used as monotherapy or in combination with antiestrogens (see) or cytostatics.
As an antitumor agent of medroxyprogesterone, acetate is mainly used for additional and (or) palliative therapy of relapses and (or) metastases of endometrial and kidney cancer, as well as for the treatment of relapses of hormone-dependent breast cancer in postmenopausal women.
The drug is administered orally or intramuscularly.
Medroxyprogesterone Prover is available in two forms: a) Provera tablets and b) Depot Prove suspension.
Prover tablets are prescribed orally for endometrial and kidney cancer from 200 to 600 mg per day, for breast cancer - from 400 to 1200 mg per day. The effect is usually observed after 8 to 10 weeks from the start of treatment.
Depo-prover is administered intramuscularly in the form of a suspension (150 mg of the drug in 1 ml) for endometrial and kidney cancer of 400-1000 mg once a week. When the condition improves, the dose is reduced to 400 mg and administered once a month.
For breast cancer, 500 mg are administered daily for 28 days, then 500 mg 2 times a week until the effect remains.
With the progression of the disease, medroxyprogesterone acetate therapy is discontinued (as with other similar drugs).
Possible side effects and contraindications are basically the same as when using other gestagens.
When using the suspension, seals and sterile abscesses at the injection site are possible.
Method of release: tablets of 100; 200; 250; 400 mg (0.1; 0.2; 0.25; 0.4 g); suspension for oral administration containing 500 mg in 1 ml: suspension for intramuscular injection (depot-proof) in 3, 3 ml bottles (500 mg or 150 mg in 1 ml) and 6, 7 ml (1000 mg).